Epinephrine Regulation of the Endothelial Nitric-oxide Synthase

ROLES OF RAC1 AND β3-ADRENERGIC RECEPTORS IN ENDOTHELIAL NO SIGNALING*

Received for publication, August 15, 2007, and in revised form, September 4, 2007. Published, JBC Papers in Press, September 12, 2007. DOI 10.1074/jbc.M706815200

Ruqin Kou and Thomas Michel

From the Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115

β-Adrenergic receptors (βAR) play an important role in vasodilation, but the mechanisms whereby adrenergic pathways regulate the endothelial isoform of nitric-oxide synthase (eNOS) are incompletely understood. We found that epinephrine significantly increases eNOS activity in cultured bovine aortic endothelial cells (BAEC). Epinephrine-dependent eNOS activation was accompanied by an increase in phosphorylation of eNOS at Ser1179 and with decreased eNOS phosphorylation at the inhibitory phosphoresidues Ser116 and Thr497. Epinephrine promoted activation of the small G protein Rac1 and also led to the activation of protein kinase A. All of these responses to epinephrine in BAEC were blocked by the β3AR blocker SR59230A. We transfected and validated duplex small interfering RNA (siRNA) constructs to selectively “knock down” specific signaling proteins in BAEC. siRNA-mediated knockdown of Rac1 completely blocked all β3AR signaling to eNOS and also abrogated epinephrine-dependent cAMP-dependent protein kinase (PKA) and Akt activation. However, siRNA-mediated knockdown of PKA did not affect Rac1 activation by epinephrine but did attenuate Akt activation by epinephrine. These findings indicate that Rac1 is an upstream regulator of β3AR signaling to PKA and to eNOS and identify a novel β3AR→Rac1→PKA→Akt pathway in endothelium. We exploited the p21-activated kinase pulldown assay to identify proteins associated with activated Rac1 and found that epinephrine stimulated the association of eNOS with Rac1; epinephrine-stimulated eNOS-Rac1 interactions were blocked by the β3AR antagonist SR59230A. Co-transfection of eNOS cDNA with constitutively active Rac1 enhanced β3AR-promoted eNOS-Rac1 association; co-transfection of eNOS with dominant negative Rac1 completely blocked the eNOS-Rac1 association. We also found that epinephrine-induced Rac1→PKA→Akt pathway mediates β3AR-mediated endothelial cell migration. Taken together, our data establish that the small G protein Rac1 is a key regulator of β3AR signaling in cultured aortic endothelial cells with potentially important implications for the pathways involved in adrenergic modulation of eNOS pathways in the vascular wall.

The sympathetic nervous system is a key determinant of vascular homeostasis and is implicated in many cardiovascular diseases that are associated with activation of neurohumoral pathways involving adrenergic receptor activation in the vasculature (1–4). Distinct adrenergic receptor subtypes serve different roles in vasoregulation, and the differential roles of adrenergic signaling pathways in the vasculature have been extensively studied over many years. The classical model for adrenergic control of vasomotor tone involves α1-adrenergic receptors in contraction of vascular smooth muscle, whereas β2-adrenergic receptors typically mediate the effects of catecholamines on relaxation of vascular smooth muscle. However, the more recent identification of β3-adrenergic receptor subtypes (5) and the characterization of the complex vascular phenotypes of adrenergic receptor “knock-out” mice (6, 7) have challenged the classical concepts of adrenergic receptor subtypes in vascular regulation. Numerous publications (for reviews, see Refs. 8 and 9) have explored the roles of adrenergic agonists and antagonists in regulation of the endothelial isoform of nitric-oxide synthase (eNOS), an enzyme that is a key determinant of blood pressure and cardiac myocyte function. In different tissues and experimental systems, diverse adrenergic receptor subtypes, including α1 (10, 11), α2 (12, 13), β1 (14), β2 (15, 16), and β3 (17, 18) adrenergic receptors, have been implicated in the modulation of eNOS, but the pathways involved in the molecular regulation of eNOS by adrenergic pathways remain incompletely understood.

eNOS is a Ca2+/calmodulin-dependent enzyme that is activated in response to the stimulation of a variety of Ca2+-mobilizing cell surface receptors in vascular endothelium and in cardiac myocytes. The activity of eNOS is also modulated by enzyme phosphorylation of multiple sites in the protein: phosphorylation at Ser1179 activates eNOS, but phosphorylation at Thr497 or Ser116 is associated with inhibition of eNOS activity (19–23). Of these phosphorylation sites, the regulation of eNOS Ser1179 has been most extensively characterized. Protein kinase Akt modifies eNOS at this residue, but other protein kinases, including the cAMP-dependent protein kinase (PKA), also have been implicated in eNOS Ser1179 phosphorylation in

*This work was supported in part by National Institutes of Health Grants HL46457, HL48743, and GM36259. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

†To whom correspondence should be addressed: Cardiovascular Division, Brigham and Women’s Hospital, Thorn Bldg., Rm. 1210A, 75 Francis St., Boston, MA 02115. Tel.: 617-732-7376; Fax: 617-732-5132; E-mail: tmichel@research.bwh.harvard.edu.

2 The abbreviations used are: eNOS, endothelial isoform of nitric-oxide synthase; AR, adrenergic receptor; PKA, cAMP-dependent protein kinase; VASP, vasodilator-stimulated phosphoprotein; MAPK, mitogen-activated protein kinase; siRNA, small interfering RNA; ERK, extracellular signal-regulated kinase; FBS, fetal bovine serum; BAEC, bovine aortic endothelial cell(s); S1P, sphingosine 1-phosphate; PI3K, phosphoinositide 3-kinase; PAK, p21-activated kinase; HA, hemagglutinin; GST, glutathione S-transferase.
response to shear stress (24). The relative roles of PKA and Akt in the regulation of eNOS in response to adrenergic receptor activation have not been clearly defined. It seems plausible that adrenergic receptor regulation of eNOS will share some features in common with the pathways for regulation of eNOS by other receptors.

We have shown previously (25) that the small G protein Rac1 is an essential upstream modulator of receptor-regulated activation of kinase Akt and eNOS, but the regulation of Rac1 by adrenergic receptors has not been reported previously. Rac1 belongs to the Rho family of small GTPases and cycles between active, GTP-bound and inactive, GDP-bound states. Rac1 plays critical roles in a wide variety of endothelial cell functions, including cell migration and modulation of the cytoskeleton (25–27). The present studies established that the small G protein Rac1 is a key regulator of β2AR signaling to eNOS and suggest that Rac1 may play a central role in adrenergic modulation of NO-dependent pathways in the vascular wall.

**EXPERIMENTAL PROCEDURES**

**Materials**—Fetal bovine serum (FBS) was from Hyclone (Logan, UT). All other cell culture reagents and media were from Invitrogen. Lipofectamine 2000 and FuGEE® 6 transfection reagents were from Invitrogen and Roche Diagnostics, respectively. Anti-phospho-eNOS Ser116 antibody was from Upstate Biotechnology (Lake Placid, NY). Polyclonal antibodies directed against phospho-eNOS (Ser1177 and Thr495 in the human eNOS sequences, corresponding to Ser1179 and Thr497 in the bovine eNOS, respectively), phospho-Akt (Ser473), phospho-VASP (Ser157), phospho-ERK1/2 (Thr202/Tyr204), total protein Rac1 is a key regulator of β2AR signaling to eNOS and suggest that Rac1 may play a central role in adrenergic modulation of NO-dependent pathways in the vascular wall.

**EXPERIMENTAL PROCEDURES**

**Materials**—Fetal bovine serum (FBS) was from Hyclone (Logan, UT). All other cell culture reagents and media were from Invitrogen. Lipofectamine 2000 and FuGEE® 6 transfection reagents were from Invitrogen and Roche Diagnostics, respectively. Anti-phospho-eNOS Ser116 antibody was from Upstate Biotechnology (Lake Placid, NY). Polyclonal antibodies directed against phospho-eNOS (Ser1177 and Thr495 in the human eNOS sequences, corresponding to Ser1179 and Thr497 in the bovine eNOS, respectively), phospho-Akt (Ser473), phospho-VASP (Ser157), phospho-ERK1/2 (Thr202/Tyr204), total Akt, and total ERK were from Cell Signaling Technologies (Beverly, MA). Monoclonal antibody directed against eNOS was from BD Pharmingen. SuperSignal substrate for chemiluminescence detection and secondary antibodies conjugated with horseradish peroxidase were from Pierce. Determinations of protein abundance using immunoblot analyses were quantitated using a ChemiImager (Alphalnnotech, San Leandro, CA). Protein determinations were made with the Bio-Rad protein assay kit. The Rac activity assay kit was from Upstate Biotechnology. All other agonists and reagents were from Sigma.

**Plasmids**—Dominant negative Rac1 mutant (N17Rac1) and constitutively active Rac1 mutant (V12Rac1) cDNAs, epitope-tagged with HA peptide and subcloned into pcDNA3.1, were obtained from the University of Missouri-Rolla cDNA Resource Center. HA-tagged wild type eNOS cDNA was described previously (25).

**Duplex siRNA Targeting Constructs**—Small interfering RNA duplex oligonucleotides were purchased from Dharmaco, Inc. (Lafayette, CO) or Ambion (Austin, TX). The sequence of the siRNA duplex construct targeting PKA was 5′-GGUGGU- GAAGCUUAAAACAG-dTdT-3′, corresponding to bases 237–258 from the open reading frame of the bovine PKA catalytic subunit mRNA (GenBank accession number NM_174584). The Rac1 siRNA duplex 5′-UGCGUUUCCUGGAGAAUAAUCdTdT-3′ was extensively characterized in an earlier report (25). The duplex siRNA used as a negative control was 5′-GCCGCCUUUGUAACGCG-dTdT-3′.

**Cell Culture and Transfection**—Bovine aortic endothelial cells (BAEC) were obtained from Cell Applications, Inc. (San Diego, CA) and maintained in culture in Dulbecco’s modified Eagle’s medium supplemented with FBS (10%, v/v) as described previously (28). BAEC were plated onto gelatin-coated culture dishes and studied prior to cell confluence between passages 5 and 9. siRNA transfections were performed as described previously in detail (29). 30 nM siRNA was transfected using Lipofectamine 2000 (0.15%, v/v) following the protocol provided by the manufacturer 24 h after cells were split at 1:5 ratio; Lipofectamine 2000 was removed by changing into fresh medium containing 10% FBS 5 h post-transfection, and cells were analyzed 48 h following transfection. In some experiments, BAEC were transfected with 5 µg of plasmid cDNA using FuGEE® 6 following the instruction provided by the supplier and were analyzed 48 h after transfection.

**Cell Treatments and Immunoblot Analysis**—β3-Adrenergic receptor antagonists were solubilized in dimethyl sulfoxide and kept at −20 °C; where indicated, 0.1% dimethyl sulfoxide (v/v, final concentration) was used as vehicle control. Epinephrine was used at 1 µM in experiments unless otherwise indicated.

After drug treatments, BAEC cell lysates were prepared using a cell lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.025% sodium deoxycholate, 1 mM EDTA, 2 mM Na3VO4, 1 mM NaF, 2 µg/ml leupeptin, 2 µg/ml antipain, 2 µg/ml soybean trypsin inhibitor, and 2 µg/ml lima trypsin inhibitor). Immunoblot analyses of protein expression and phosphorylation were assessed as described previously in detail (30). Densitometric analyses of Western blots were performed using a ChemiImager HD4000 (Alphalnnotech).

**Rac1 Activity Assay**—48 h following transfection with siRNA or plasmid constructs, BAEC in 100-mm dishes were treated with agonists or inhibitors as indicated, and cells were then washed with ice-cold phosphate-buffered saline and lysed in lysis buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, 1% Igepal CA-630, 10 mM MgCl2, 1 mM EDTA, 10% glycerol, 2 mM Na3VO4, 1 mM NaF, 2 µg/ml leupeptin, 2 µg/ml antipain, 2 µg/ml soybean trypsin inhibitor, and 2 µg/ml lima trypsin inhibitor). Pulldown of the GTP-bound active form of Rac1 was performed by incubating the cell lysates with GST fusion protein corresponding to the p21-binding domain of PAK-1 bound to glutathione-agarose (Upstate Biotechnology) for 1 h at 4 °C following the instructions provided by the supplier. The beads were washed three times with lysis buffer, and the proteins bound to the beads were eluted with Laemmli sample buffer and analyzed for the amount of GTP-bound Rac in immunoblots probed with a Rac monoclonal antibody (Upstate Biotechnology); in some experiments, eNOS co-precipitated with the beads was detected in immunoblots probed with an eNOS monoclonal antibody.

**eNOS Activity Assay**—eNOS activity in intact BAEC was quantified by measuring the formation of 1–[3H]citrulline from 1–[3H]arginine as described previously (31, 32). Briefly the reaction was initiated by adding 1–[3H]arginine (10 µCi/ml, diluted with unlabeled 1–arginine to give a final concentration of 10 µM) plus various drug treatments as described below. Each treatment was performed in duplicate cultures, which were analyzed in duplicate. NOS activity, measured as 1–citrulline formation,
β3-Adrenergic Receptors and eNOS Activation

was expressed as fmol of L-citrulline produced/mg of cellular protein/min).

Endothelial Cell Migration Assay—Cell migration was assayed using a Transwell cell culture chamber containing polycarbonate membrane inserts with 8-μm pore size (Corning Costar Corp.). BAEC were maintained in Dulbecco’s modified Eagle’s medium supplemented with 0.4% FBS for 18 h before migration experiments. In some experiments, cells were transfected with control, Rac1-specific, or PKA-specific siRNA, and migration experiments were performed 48 h after transfection. Cells were detached by trypsin-EDTA treatment and resuspended in Dulbecco’s modified Eagle’s medium, 10% FBS. 5 × 10⁴ cells in Dulbecco’s modified Eagle’s medium, 0.4% FBS were added to the upper chamber. The bottom chamber was filled with 600 μl of Dulbecco’s modified Eagle’s medium, 0.4% FBS medium, and the assembly was incubated at 37 °C for 1 h to allow cells to adhere to the membrane. Agonist was added into the lower chamber, and the chambers were incubated at 37 °C overnight to allow cell migration. In some experiments, vehicle or inhibitor as indicated was added into the lower chamber 1 h prior to adding agonist. The Transwell inserts were transferred into a new plate containing 1 ml of 0.05% trypsin-EDTA solution to detach the cells from the membrane. Cells in the lower chamber were counted with a hemocytometer. Each treatment was measured in duplicate, and each sample was counted twice in four 4 × 4 square fields.

Other Methods—All experiments were performed at least three times. Mean values for individual experiments were expressed as mean ± S.E. EC₅₀ values were determined by analysis of Eadie-Hofstee plots based on the Michaelis-Menten equation. Statistical differences were assessed by analysis of variance or paired t test as indicated. A p value less than 0.05 was considered statistically significant.

RESULTS

Epinephrine Induces Rac1 Activation—We have shown previously that Rac1 is an upstream regulator of eNOS signaling in cultured endothelial cells (25). The current experiments explored the activation of Rac1 in endothelial signal transduction pathways elicited by the adrenergic agonist epinephrine. Fig. 1A shows a time course of Rac1 activation following stimulation of BAEC with epinephrine (1 μM); Rac1 activation was quantitated in a pulldown assay of active GTP-Rac1 using the p21-binding domain of PAK-1 as described above. Fig. 1B shows a dose response of Rac1 activation analyzed 5 min after agonist addition. Immunoblots from the pulldown assay were probed with antibody against Rac to measure Rac1 activation; the cell lysates were probed with antibodies directed...
against other signaling proteins as shown. Densitometric analysis of pooled data from three experiments showed that epinephrine stimulation promoted activation of Rac1 by 2.4 ± 0.5-fold \((n = 3, p < 0.05)\); the maximal effect was seen at 5 min following addition of epinephrine and persisted for at least 30 min. Analyses of dose-response experiments (Fig. 1B) established that epinephrine was a potent activator of Rac1 with an \(EC_{50}\) of 27 ± 7 nM \((n = 5)\). Analysis of immunoblots probed with the phospho-VASP-Ser\(^{157}\)-specific antibody revealed that epinephrine treatment promoted phosphorylation of vasodila-

tor-stimulated phosphoprotein (VASP) at Ser\(^{157}\), the site on VASP that undergoes phosphorylation by PKA (33). The time course (Fig. 1A) and dose response (Fig. 1B) of VASP phosphorylation paralleled that of epinephrine-induced Rac1 activation. Equivalent loading was confirmed in immunoblots that showed no effect of epinephrine on the abundance of total eNOS or Rac1.

**Rac1 and \(\beta\)-AR Mediate Epinephrine-induced eNOS Activation in BAEC**—We next used siRNA methods to explore the role of Rac1 in epinephrine-induced eNOS activation. Cultured BAEC were transfected with control or Rac1 siRNA, and the effects of epinephrine on eNOS activity were analyzed 48 h following transfection by measuring the conversion of \(\L-[\text{3H}]\text{arginine to } \L-[\text{3H}]\text{citrulline as described under “Experimental Procedures.” As shown in Fig. 2A, epinephrine stimulation induced a 1.8 ± 0.4-fold increase of eNOS activity (from 3.8 ± 0.3 to 6.8 ± 1.1 fmol/min/mg of protein, \(p < 0.05, n = 3\)), siRNA-mediated knockdown of Rac1 completely blocked epinephrine-induced eNOS activation \((p < 0.05, n = 3)\). Fig. 2B shows the pooled data for dose-response experiments analyzing epinephrine-promoted eNOS activation that established that epinephrine promoted a 2.4 ± 0.3-fold \((n = 3, p < 0.05)\) increase in eNOS activity, which is sufficient to promote coronary vasorelaxation (34), with an \(EC_{50}\) of 25 ± 7 nM \((n = 3)\). Fig. 2C shows that epinephrine-induced eNOS activation was blocked by the non-selective \(\beta\)-adrenergic receptor antagonist propranolol, whereas the \(\alpha\)-adrenergic receptor blocker phentolamine had no effect on epinephrine-induced eNOS activation.

**Epinephrine Promotes Differential Phosphorylation and Dephosphorylation of eNOS**—We next studied the effects of epinephrine on phosphorylation of key signaling proteins in BAEC with a focus on eNOS phosphorylation. We exploited phosphorylation site-specific antibodies to probe immunoblots prepared from BAEC treated with epinephrine for varying times (Fig. 3, A and B) or at different epinephrine doses (Fig. 3, C and D). Epinephrine promoted an increase in the phosphorylation of eNOS at Ser\(^{179}\); phosphorylation of eNOS at this residue has been shown to increase enzyme activity (19). As also
shown in Fig. 3, epinephrine treatment promoted the dephosphorylation of eNOS at two sites (Thr⁴⁹⁷ and Ser¹¹⁶) that inhibit the enzyme when phosphorylated (22, 23). Thus, the increase in eNOS enzyme activity seen with epinephrine treatment (Fig. 2) is accompanied by an increase in enzyme phosphorylation at an activating residue and a decrease in phosphorylation at two inhibitory residues. The change in phosphorylation at Ser¹¹⁷⁹ and Thr⁴⁹⁷ was seen within 2 min of epinephrine addition, whereas eNOS dephosphorylation at Ser¹¹⁶ was seen only after 15 min of drug addition and persisted for at least an hour (Fig. 3B). Other signaling proteins also underwent robust phosphorylation following epinephrine treatment as shown in Fig. 3. Epinephrine induced the rapid and persistent phosphorylation of the PKA substrate VASP (6.2 ± 0.9-fold increase in phospho-

**FIGURE 4.** Effects of selective adrenergic antagonists on epinephrine-induced modulation of eNOS phosphorylation. A, immunoblots were analyzed in epinephrine-treated BAEC that were pretreated with the β³ AR blocker atenolol, β² AR blocker butoxamine, or β¹ AR blocker SR59230A for 30 min. The cell lysates were resolved by SDS-PAGE and analyzed in immunoblots probed separately, as indicated, with specific antibodies directed against Ser¹¹⁶-phospho-eNOS (p-eNOS¹¹⁶), Thr⁴⁹⁷-phospho-eNOS (p-eNOS⁴⁹⁷), Ser¹¹⁷⁹-phospho-eNOS (p-eNOS¹¹⁷⁹), Ser¹⁵⁷-phospho-VASP (p-VASP¹⁵⁷), phospho-ERK (p-ERK), and total Akt, ERK, and eNOS. The experiment shown is a representative of three independent experiments that yielded similar results. B, pooled data from multiple experiments quantitating the relative abundances (normalized to the intensity of the total eNOS loading control) of Ser¹¹⁶-phospho-eNOS, Thr⁴⁹⁷-phospho-eNOS, Ser¹¹⁷⁹-phospho-eNOS, phospho-VASP, and phospho-ERK in BAEC treated as described in A. The results were obtained from three to six independent experiments. Basal phosphorylation in vehicle-treated cells was defined as 1.0. The effects of β³ AR blocker SR59230A on epinephrine-induced alteration of eNOS phosphorylation were statistically significant at the p < 0.01 level (by analysis of variance). C, results of Rac1 activation by epinephrine; Rac1 activity was assayed using the GST-PAK pulldown technique as described under “Experimental Procedures.” Confluent BAEC were pretreated with control or β³ AR blocker SR59230A for 30 min and then stimulated with 1 μM epinephrine for 5 min. Active Rac1 and total Rac were detected in immunoblots probed with anti-Rac, -eNOS, and -phosphospecific VASP antibodies, respectively. D, pooled data from multiple experiments quantitating the relative abundances of active Rac1 (normalized to the intensity of the total Rac loading control). Basal phosphorylation in vehicle-treated cells was defined as 1.0. The effects of β³ AR blocker SR59230A on epinephrine-induced Rac1 activation were statistically significant at the p < 0.01 level (by analysis of variance), compared with control (*) or epinephrine (#) treatments.
β3-Adrenergic Receptors and eNOS Activation

FIGURE 5. Effects of protein kinase inhibitors on epinephrine-induced regulation of eNOS phosphorylation. A, the results of immunoblots prepared from 1 μM epinephrine-treated BAEC. Prior to epinephrine treatment, cells were pretreated with control, phosphoinositide 3-kinase inhibitor wortmannin (Wort), MAPK kinase inhibitor U0126, or Src kinase inhibitor PP2 for 30 min. The cell lysates were resolved by SDS-PAGE and analyzed in immunoblots probed separately, as indicated, with specific antibodies directed against Ser116-phospho-eNOS (p-eNOS116), Thr497-phospho-eNOS (p-eNOS497), Ser1179-phospho-eNOS (p-eNOS1179), Ser157-phospho-VASP (p-VASP157), phospho-Akt (p-Akt), and phospho-ERK (p-ERK), and total ERK. B, pooled data from multiple experiments quantitating the relative abundance (normalized to the intensity of the total eNOS loading control) of Ser116-phospho-eNOS, Thr497-phospho-eNOS, Ser1179-phospho-eNOS, phospho-VASP, phospho-Akt, and phospho-ERK in BAEC treated as described in A. The results were obtained from three to six independent experiments. Basal phosphorylation in vehicle-treated cells was defined as 1.0. * indicates p < 0.05 for epinephrine (Epi) versus vehicle treatment; # indicates p < 0.05 for pharmacological reagent versus vehicle in epinephrine-treated cells.
Effects of Subtype-specific β-Adrenergic Antagonists on Epinephrine Responses in Endothelial Cells—We next determined the β-adrenergic subtype that mediates these epinephrine-mediated responses in BAEC using a series of subtype-selective antagonists to block epinephrine action as determined in immunoblot analyses of endothelial cell lysates that were probed with various phosphorylation state-specific antibodies. As shown in Fig. 4, neither the β1 AR blocker atenolol nor the β2 AR blocker butoxamine substantially affected epinephrine-modulated phosphorylation pathways involving eNOS, VASP, or ERK. By contrast, the specific β3 AR blocker SR59230A completely blocked epinephrine-induced phosphorylation of eNOS Ser1179 and dephosphorylation of eNOS Ser116 and eNOS Thr497 and also completely blocked epinephrine-induced phosphorylation of VASP and ERK1/2. We also explored the effects of the β3 AR blocker SR59230A on epinephrine-stimulated Rac1 activation. As shown in Fig. 4, C and D, epinephrine-promoted Rac1 activation was completely abolished by pretreatment with β3 AR blocker SR59230A. Taken together, these data indicate that β3 AR is the major receptor for epinephrine signaling in BAEC.

Effects of Kinase Inhibitors on Epinephrine Responses in Endothelial Cells—The next series of experiments explored the effects of a series of protein kinase inhibitors on epinephrine-modulated phosphorylation responses in BAEC. As shown in Fig. 5, pretreatment of BAEC with the PI3K inhibitor wortmannin completely blocked epinephrine-induced phosphorylation of Akt, a well known PI3K substrate. However, wortmannin had no effect on epinephrine-induced modulation of eNOS phosphorylation at Ser116, Thr497, or Ser1179 nor was there any effect of wortmannin on ERK1/2 or VASP phosphorylation. Pretreatment of BAEC with the MAPK kinase inhibitor U0126 completely blocked epinephrine-induced ERK phosphorylation without affecting epinephrine-induced phosphorylation of eNOS, VASP, or Akt. By contrast, pretreatment with the Src kinase inhibitor PP2 completely blocked epinephrine-mediated phosphorylation of Akt and eNOS Ser1179 without affecting epinephrine-induced dephosphorylation of eNOS Ser116 and Thr497 and without altering the epinephrine-induced phosphorylation of VASP and ERK.

siRNA-mediated Rac1 Knockdown Attenuates β3-AR-mediated Responses—The next series of experiments used siRNA approaches to explore the role of Rac1 in epinephrine-mediated eNOS phosphorylation and dephosphorylation. As shown in Fig. 6, Rac1 siRNA-mediated Rac1 knockdown decreased the basal level eNOS phosphorylation at Ser116 and Thr497 residues and blocked epinephrine-induced phosphorylation of eNOS1179 as well as dephosphorylation of eNOS116 and eNOS497. Knockdown of Rac1 also attenuated epinephrine-induced phosphorylation of PKA substrate VASP, suggesting that
Rac1 is an upstream regulator of the PKA substrate VASP as well as a key determinant of eNOS responses. We then designed an siRNA targeting construct to knock down PKA expression, transfected this siRNA into BAEC, and performed the Rac1 activity assay as described above. As shown in Fig. 6, C and D, epinephrine-induced Rac1 activation was not affected by siRNA-mediated PKA knockdown: this PKA-specific siRNA led to a ~90% knockdown of PKA without affecting Rac1 activation, indicating that Rac1 indeed is “upstream” of PKA.

Epinephrine Induces eNOS-Rac1 Association—These findings place Rac1 as a key upstream mediator of β3AR signaling to eNOS, and we next designed experiments to determine whether epinephrine may more directly modulate interactions between eNOS and Rac1. We modified the Rac1 activity assay to explore whether eNOS itself may associate with Rac1. After performing the Rac1 “pulldown” assay using the GST-PAK domain to isolate active Rac1, we probed the eluate from this pulldown assay using the eNOS antibody. We were intrigued to find that epinephrine increased the association between an activated Rac1 and eNOS (Fig. 7). This response was highly reproducible, and we found that epinephrine stimulation promoted the eNOS presence in the GST-PAK pulldown fraction by 1.9 ± 0.2-fold (n = 4, p < 0.05) in a time- (Fig. 7A) and dose-dependent (Fig. 7B) manner. The EC50 for this effect (30 ± 6 nM, n = 3, p < 0.05) is similar to the EC50 for the other epinephrine-induced signaling responses seen in these studies (see Figs. 1–4). To document that Rac1 is required for the GST-PAK-mediated pulldown of eNOS, we used Rac1 siRNA to knock down Rac1 expression and found that eNOS pulldown was completely abrogated following Rac1 knockdown (Fig. 7, C and D). We used a complementary experimental approach to explore the eNOS-Rac1 association, exploiting plasmids expressing dominant negative or constitutively active Rac1. As shown in Fig. 7, E and F, BAEC were co-transfected with HA-tagged eNOS plus either the HA-tagged constitutively active Rac1 V12 mutant or the HA-tagged dominant negative Rac1 N17, and we then performed the GST-PAK pulldown assay and probed for HA-eNOS and HA-Rac1 in an immunoblot; empty vector served as control. As shown in Fig. 7E, transfection of the constitutively active Rac1 mutant led to increased...
Reduced endothelial cell migration was attenuated by the nephrine-treated cells.

**FIGURE 8.** β3AR activation promotes eNOS-Rac1 association. A, immunoblots were analyzed in either vehicle- or epinephrine-treated BAEC cultures after vehicle or β3 receptor blocker SR59230A treatment for 30 min. Cell lysates were harvested at 5 min following addition of epinephrine (1 μM), pulled down by GST-PAK beads, and resolved by SDS-PAGE. Some of the lysates were directly subjected to SDS-PAGE. The gels were transferred onto nitrocellulose membrane and analyzed in immunoblots probed separately with antibodies directed against total eNOS, Rac, or Ser157-phospho-VASP (p-VASP157). The experiment shown is a representative of three independent experiments that yielded similar results. B, Rac1 association seen in the control cells. As shown in Fig. 8, the β3AR antagonist SR59230A completely blocked epinephrine-induced association between eNOS and Rac1.

**Epinephrine-induced BAEC Migration—**Rac1 is a well known mediator of endothelial cell migration (25), and we next explored the effects of epinephrine on BAEC migration. We conducted cell migration assays using a Transwell cell culture chamber. As shown in Fig. 9, epinephrine induced a 2-fold increase in cell migration (n = 6, p < 0.05). Epinephrine-induced endothelial cell migration was attenuated by the β3AR antagonist SR59230A and by the PI3K inhibitor wortmannin as well as the Src kinase inhibitor PP2. In contrast, the MAPK kinase inhibitor PD98059 did not block epinephrine-induced cell migration. Transfection of BAEC with Rac1 or PKA siRNA completely blocked epinephrine-induced BAEC migration (Fig. 9B).

**DISCUSSION**

We pursued pharmacological approaches along with protein overexpression experiments and siRNA-mediated knockdown methods to study the molecular mechanisms involved in epinephrine signaling to eNOS in cultured endothelial cells. These studies identified a key role for the small G protein Rac1 as an upstream modulator of β3-adrenergic receptor-mediated eNOS activation by epinephrine and point to a central role for a novel Rac1 → PKA → Akt pathway in the modulation of cellular and molecular responses induced by epinephrine in the vascular endothelium.

These studies identified Rac1 as an essential mediator of epinephrine-induced β3-adrenergic receptor-mediated eNOS activation. The relationship between the Gs-coupled β3-adrenergic receptors and small G proteins is incompletely understood, and activation of Rac1 by β3-adrenergic receptors has not been reported previously. The EC50 values of the effect of epinephrine on Rac1 activation (~30 nm) and for the activation of other endothelial signaling pathways in endothelial cells are within a physiological range (see Figs. 1–4 and 7) and are similar to the EC50 values determined for epinephrine-induced β3-adrenergic responses in other experimental systems (35). Moreover the degree of epinephrine-induced eNOS activation that we observed in those studies (2.4-fold increase; see Fig. 2) is of a sufficient magnitude to cause vasodilation (34). siRNA-mediated knockdown of Rac1 completely blocked epinephrine-induced eNOS activation (Fig. 2). We have previously docu-
**β3-Adrenergic Receptors and eNOS Activation**

mented a key role for Rac1 in the activation of eNOS by the lipid mediator sphingosine 1-phosphate (25). The S1P response is modulated by S1P1 receptors that are coupled to Go (36, 37), whereas β3-adrenergic receptors are coupled to G12/13 pathways (38). It thus appears that the small G protein Rac1 may be a downstream effector of both Gα12/13 as well as Gα13-coupled receptors.

These studies used pharmacological approaches to establish that it was the β3 subtype of adrenergic receptors that mediated the eNOS response to epinephrine in these cells (Fig. 4). The α-adrenergic antagonist phenotlamine had no effect on the epinephrine response, and the β3-selective adrenergic antagonist SR59230A was the only subtype-specific blocker that attenuated the effects of epinephrine. These results are consistent with a recent report that also describes the β3-adrenergic modulation of eNOS in BAEC (34) but stand in contrast to a prior publication (34) found that only the this same cell type. Like the present findings, the authors of this recent publication (34) found that only the β3 subtype of adrenergic receptors modulates eNOS responses in BAEC and reported no evidence for involvement of α3-adrenergic vascular responses in this same cell type. Like the present findings, the authors of this earlier study (39) are not clear but may relate to differences in culture conditions and/or experimental design.

The eNOS phosphorylation response to β3-adrenergic receptor stimulation in these cultured endothelial cells appears to be particularly complex. Epinephrine promoted an increase in eNOS phosphorylation at the activating phosphoresidue Ser1179 accompanied by a marked decrease in phosphorylation at the inhibitory phosphoresidues Ser116 and Thr497 (Fig. 3). Yet we and others have shown previously that other eNOS agonists, such as S1P, promote Ser1179 phosphorylation without affecting phosphorylation at either Ser116 or Thr497, and still other agonists (such as vascular endothelial growth factor) appear to promote Ser1179 phosphorylation and Ser116 dephosphorylation without having any effect on Thr497. Moreover eNOS phosphorylation at this site can affect enzyme dephosphorylation at another site (40). All the effects of epinephrine on eNOS phosphorylation do appear to be modulated by Rac1 because siRNA-mediated Rac1 knockdown blocked epinephrine modulation of all these eNOS phosphorylation sites (Fig. 6), whereas ERK1/2 phosphorylation was unaffected (data not shown). The relative roles of phosphoinositide 3-kinase, Src kinase, and mitogen-activated protein kinases in the β3-adrenergic response in these cells also appear to be complexly determined: as shown in Fig. 5, treatment of BAEC either with the phosphoinositide 3-kinase inhibitor wortmannin or the mitogen-activated protein kinase inhibitor U0126 left all eNOS phosphorylation responses intact (while clearly blocking their target kinases), yet the Src kinase inhibitor PP2 quite clearly blocked epinephrine-induced Ser1179 phosphorylation while leaving the dephosphorylation of Ser116 and Thr497 unaffected. The relative roles of kinase Akt and PKA in eNOS regulation have been explored in many prior studies (41). Unlike most agonists, we found that epinephrine-induced eNOS activation was totally independent of activation of Akt because inhibition of the PI3K/Akt pathway by wortmannin had no effect either on epinephrine-induced eNOS Ser1179 phosphorylation or on the epinephrine-dependent dephosphorylation of Ser116 and Thr497. It seems likely that these complex patterns of agonist-specific protein kinase activation permit the modulation of cellular responses in a highly specialized manner.

We were very intrigued to find that epinephrine induced the association of eNOS with activated Rac1 (Fig. 7). We discovered this association in experiments using eNOS antibody to probe an immunoblot prepared from the eluate of the GST-PAK pull-down from endothelial cell lysates from epinephrine-treated cells. This novel effect of epinephrine was observed to have a time course and dose response similar to other epinephrine-mediated responses in these cells (Figs. 1 and 3). The PAK pull-down assay can isolate other Rho family complexes, but the fact that siRNA-mediated Rac1 knockdown abrogated eNOS pull-down strongly indicates that Rac1 is the active G protein that associates with eNOS in this complex. We pursued a second independent experimental approach that also provided evidence for the association of eNOS with Rac1: co-transfection of eNOS with dominant negative form of Rac1 completely blocked epinephrine-induced eNOS, whereas co-transfection of eNOS with the constitutively active form of Rac increased basal as well as epinephrine-induced eNOS-Rac1 association (Fig. 8). We have shown previously that both Rac1 and eNOS are targeted to plasmaemmal caveolae in endothelial cells, and thus both proteins are located in the same subcellular organelle, thereby providing a cellular locale in which these two proteins could reversibly associate. Of course, the fact that eNOS can be pulled down by GST-PAK does not of course establish that eNOS and Rac1 directly interact with one another. However, these findings represent clear evidence that eNOS and Rac1 reversibly form an agonist-modulated complex that is sufficiently stable that it may be recovered using protein chemical approaches. We speculate that the eNOS-Rac1 association could regulate eNOS phosphorylation because siRNA-mediated down-regulation of Rac1 not only completely blocked epinephrine-induced Ser1179 phosphorylation but also attenuated basal phosphorylation at Ser116 and Thr497 phosphorylation as well as all epinephrine-mediated responses.

As shown in Fig. 9, epinephrine promoted endothelial cell migration via β3-adrenergic receptors. Epinephrine-stimulated migration was completely attenuated by the β3-adrenergic antagonist SR95230A and was also blocked by the transfection of siRNA constructs targeting Rac1 or PKA. These observations suggest that both Rac1 and PKA play an essential role in β3-adrenergic receptor regulation of endothelial cell migration. As we found previously for S1P-induced endothelial cell migration, which also depends on Rac1 activation (25), we found in the present studies (Fig. 9) that the PI3K inhibitor wortmannin also inhibited epinephrine-stimulated endothelial cell migration. Thus, although epinephrine-dependent eNOS activation was insensitive to wortmannin (Fig. 5), the PI3K/Akt pathway still appears to modulate the epinephrine-modulated increase in endothelial cell migration. These latter observations are consistent with a prior report (42), which showed that the β3 agonist BRL37344 promotes human retinal endothelial cell migration by the PI3K/Akt pathway. Despite the fact that β3-adrenergic receptor signaling to eNOS did not involve PI3K/Akt (Fig. 5), other β3-adrenergic responses, including modulation of endothelial cell migration, clearly involve the PI3K/Akt pathway.
β3-Adrenergic Receptors and eNOS Activation

pathway. Taken together, these observations suggest that β3-adrenergic receptor activation of the Rac1 → PKA → Akt pathway may play an important role in endothelial cell migration and angiogenesis.

In summary, these studies demonstrated that the small GTPase Rac1 serves a regulatory role that appears to be upstream of many of the signaling pathways that are activated in response to epinephrine in cultured endothelial cells. Our findings establish that Rac1 modulates β3-adrenergic receptor-mediated eNOS activation in endothelial cells and support a role for a Rac1 → PKA → Akt pathway that functions as a determinant of endothelial migration induced by epinephrine. The inter-relationships between β3-adrenergic receptors and other receptor-activated pathways involving Rac1 may importantly influence NO-modulated signaling pathways in the vascular wall.

REFERENCES

1. Saucerman, J. J., and McCulloch, A. D. (2006) Ann. N. Y. Acad. Sci. 1080, 348–361
2. Brum, P. C., Rolim, N. P., Bacurau, A. V., and Medeiros, A. (2006) An. Acad. Bras. Cienc. 78, 485–503
3. Rozec, B., and Gauthier, C. (2006) Pharmacol. Ther. 111, 652–673
4. Balligand, J. L. (2004) J. Pharmacol. Exp. Ther. 309, 13–20
5. Emorine, L. J., Marullo, S., Briend-Sutren, M. M., Patey, G., Tate, K., Delavier-Klutcho, C., and Strosberg, A. D. (1989) Science 245, 1118–1121
6. Eckhart, A. D., and Koch, W. J. (2001) J. Pharmacol. Exp. Ther. 299, 1–5
7. Philipp, M., and Hein, L. (2004) Pharmacol. Ther. 101, 65–74
8. Pott, C., Brixius, K., Bloch, W., Ziskoven, C., Napp, A., and Schwinger, R. H. (2006) Pharmacol. 61, 25–26
9. Balligand, J. L., and Cannon, P. J. (1997) Arterioscler. Thromb. Vasc. Biol. 17, 1846–1858
10. Jones, C. J., DeFilippis, D. V., Patterson, J. L., and Chilian, W. M. (1993) Circulation 87, 1264–1274
11. Gurdal, H., Can, A., and Ugur, M. (2004) Biochemistry 43, 3754–3760
12. Bryan, R. M., Jr., Eichler, M. Y., Johnson, T. D., Swafford, M. W., and Suresh, M. S. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10800–10804
13. Kou, R., Greif, D., and Michel, T. (2002) J. Biol. Chem. 277, 29669–29673
14. Chen, X., Minatoguchi, S., Arai, M., Wang, N., Lu, C., Narento, Y., Uno, Y., Misao, Y., Takemura, G., Li, C., and Fujiwara, H. (2007) J. Biol. Chem. 282, 4704–4711
15. Igarashi, J., Bernier, S. G., and Michel, T. (2001) Circulation 103, 1031–1036
16. Lee, O. H., Lee, D. J., Kim, Y. M., Kim, Y. S., Kwon, H. J., Kim, K. W., and Chung, M. J. (2004) J. Biol. Chem. 279, 3969–3974
17. Dessy, C., Salies, J., Ghisdal, P., Daneau, G., Lobysheva, I. L., Fréart, F., Belge, C., Jnaou, K., Noirehomme, P., Feron, O., and Balligand, J. L. (2005) Circulation 112, 1198–1205
18. Brixius, K., Bloch, W., Pott, C., Napp, A., Krahwinkel, A., Ziskoven, C., Koriller, M., Mehlihorn, U., Hescheler, J., Fleischmann, B., and Schwinger, R. H. (2004) Br. J. Pharmacol. 143, 1014–1022
19. Fulton, D., Gratton, J. P., McCabe, T. J., Fontana, J., Fujiy, K., Walsh, K., Franke, T. F., Papapetropoulos, A., and Sessa, W. C. (1999) Nature 399, 597–601
20. Michel, B. J., Griffiths, J. E., Mitchelhill, K. I., Rodriguez-Crespo, I., Tiganis, T., Bozinovski, S., de Montellano, P. R., Kemp, B. E., and Pearson, R. B. (1999) J. Biol. Chem. 274, 845–848
21. Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., and Zeiher, A. M. (1999) J. Biol. Chem. 399, 601–605
22. Kou, R., Greif, D., and Michel, T. (2002) J. Biol. Chem. 277, 29669–29673
23. Harris, M. B., Ju, H., Venema, V. J., Liang, H., Zou, R., Michell, J. B., Chen, Z. P., Kemp, B. E., and Venema, R. C. (2001) J. Biol. Chem. 276, 16587–16591
24. Boo, Y. C., Sorescu, G., Boyd, N., Shioji, M., Walsh, K., Du, J., and Ho, J. (2002) J. Biol. Chem. 277, 3388–3396
25. Gonzalez, E., Kou, R., and Michel, T. (2006) J. Biol. Chem. 281, 3210–3216
26. Hu, Y. L., Li, S., Miao, H., Tsou, T. C., del Pozo, M. A., and Chien, S. (2002) J. Vasc. Res. 39, 465–476
27. Waschke, J., Drenckhahn, D., Adamson, R. H., and Curry, F. E. (2004) Am. J. Physiol. 287, H704–H711
28. Michel, T., Li, G. K., and Busconi, L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6252–6256
29. Gonzalez, E., Nagiel, A., Lin, A. J., Golan, D., and Michel, T. (2004) J. Biol. Chem. 279, 40659–40669
30. Busconi, L., and Michel, T. (1994) J. Biol. Chem. 269, 25016–25020
31. Chol, Z., Yuhanna, I. S., Galcheva-Gargova, Z., Karas, R. H., Mendelsohn, M. E., and Shaul, P. W. (1999) J. Clin. Invest. 103, 401–406
32. Kou, R., Igarashi, J., and Michel, T. (2002) Biochemistry 41, 4982–4988
33. Comerford, K. M., Lawrence, D. W., Synnestvedt, K., Levi, B. P., and Collan, S. P. (2002) FASEB J. 16, 583–585
34. Dessy, C., Moniotte, S., Ghisdal, P., Havaux, X., Noirehomme, P., and Balligand, J. L. (2004) Circulation 110, 948–954
35. Bronnikov, G., Bengtsson, T., Kramarova, L., Golozoubova, V., Cannon, B., and Nedergaard, J. (1999) Endocrinology 140, 4185–4197
36. Lee, O. H., Lee, D. J., Kim, Y. M., Kim, Y. S., Kwon, H. J., Kim, K. W., and Kwon, Y. G. (2000) Biochem. Biophys. Res. Commun. 268, 147–153
37. Igarashi, J., Bernier, S. G., and Michel, T. (2001) J. Biol. Chem. 276, 12420–12426
38. Bacic, F., McCarron, R. M., Uematsu, S., and Spatz, M. (1992) Metab. Brain Dis. 7, 125–137
39. Liao, J. K., and Homey, C. J. (1992) Circ. Res. 70, 1018–1026
40. Greif, D. M., Kou, R., and Michel, T. (2002) Biochemistry 41, 15845–15853
41. Kendall, M. J. (1989) J. Cardiovasc. Pharmacol. 14, Suppl. 7, 59–68
42. Steinle, J. J., Booz, G. W., Meininger, C. J., Day, J. N., and Granger, H. J. (2003) J. Biol. Chem. 278, 20681–20686